心力衰竭研究的组学视角

The omics perspective on heart failure research

心力衰竭是多种心血管疾病的终末阶段,严重影响了全世界近4000万人的生活质量及生命安全。目前还有部分类型心力衰竭的临床特征、病理生理特点不清楚,无有效的诊断及治疗方法。近年来,基因组学、转录组学、表观基因组学、蛋白质组学、代谢组学等组学技术在疾病研究中的广泛应用,为心力衰竭的预防、诊断及治疗提供了新的策略,同时也为降低心力衰竭死亡率带来了希望。本文针对心力衰竭临床治疗现状,对各组学及其相互间的联合在心力衰竭发病机制、临床诊断治疗、相关药物药效和作用机制等方面研究中的作用及应用潜力进行了综述。

Heart failure is the end stage of many cardiovascular diseases. It seriously affects the safety and quality of life of nearly 40 million people worldwide. At present, the clinical and pathophysiological characteristics of some types of heart failure are unknown, and there is no effective diagnosis and treatment. In recent years,genomics, transcriptomics, epigenomics, proteomics, metabolomics and other omics technologies have been widely used in disease research, providing new opportunities for the prevention, diagnosis and treatment of diseases. These strategies have also brought hope for the reduction in heart failure mortality. Based on the current status of clinical treatment of heart failure, this article reviews the roles and potential applications of these various omics technologies and their opportunities in the study of the pathogenesis of heart failure, clinical diagnosis and treatment, and related drug pharmacodynamics and mechanism of action.